Global Trial Accelerators™

Mexico Manufacturing, Brazil Reform and AI in Biopharma

**bioaccess®** positions itself as a specialized contract research organization focused exclusively on first-in-human trials across Latin America's regulatory landscape. The company claims to serve 50+ clients with 40% faster timelines and 30% lower per-patient costs compared to US and European jurisdictions.

Key Points:

• Limits intake to 8 new FIH programs quarterly with 12-month service guarantees
• Operates across 10-country Latin American clinical network from offices in Miami, Bogotá, Mexico City, São Paulo, and Buenos Aires
• Targets medtech, biopharma, and radiopharma sectors seeking regulatory pathway alternatives
• Provides technical file translation services for **Colombia's** INVIMA submission requirements

Why It Matters: Selective capacity management potentially signals quality control but may create bottlenecks for medtech companies requiring immediate FIH study initiation in Latin American markets.

Technical Translation Remains Critical for Cross-Border Trials

Radiopharma Heats Up + LATAM Trials Gain Speed

Colombia's medical device regulatory framework requires strategic navigation as **INVIMA** guidelines determine market access timelines and compliance costs for international manufacturers. **bioaccess®** analysis identifies seven regulatory pathways that directly impact first-in-human study feasibility and commercial device approval processes.

Key Points:

• Pre-market notification requirements vary significantly between Class II and Class III devices, affecting timeline projections by 60-120 days
• Clinical evidence standards align with FDA 510(k) pathways for most device categories, reducing duplicate testing costs
• Local authorized representative mandates require Colombian legal entity establishment or third-party designation
• Quality management system audits follow ISO 13485 standards with **INVIMA**-specific documentation requirements
• Post-market surveillance obligations include adverse event reporting within 72 hours of manufacturer awareness

Why It Matters: Understanding **INVIMA**'s regulatory structure reduces Colombian market entry costs by an estimated 25-40% compared to navigating compliance requirements without specialized guidance.

Colombia: Unlocking Faster Clinical Trials Through INVIMA

Colombia Files Clinical Trial Reform Bill - 2-3 Year Legislative Process Ahead | Global Trial Accelerators

Colombia Files Clinical Trial Reform Bill Requiring 4 Congressional Debates

From Approval to Execution—LATAM in Focus 🇨🇴

**Colombia's** **INVIMA** faces a regulatory crisis with **12,810** pending applications as of March 2026 and a **29-month** average backlog for clinical trial approvals. **Proyecto de Ley 191** proposes replacing the 33-year-old prior-authorization system with a risk-based model featuring a **30-day** objection window for regulators.

Key Points:

• **INVIMA** operates with a **30%** budget reduction since 2023 while processing record application volumes
• Oncology trials face a **45%** molecule rejection rate under current regulatory framework
• New legislation introduces dedicated **Phase I** pathways and risk-stratified approval processes
• Reform targets the replacement of **Resolution 8430**, which has governed Colombian clinical research since 1993

Why It Matters: **Colombia's** regulatory bottleneck threatens **Latin America's** second-largest clinical trial market, making **Proyecto de Ley 191** a critical factor for medtech companies evaluating regional FIH strategies over the next 18 months.

Colombia’s New Law Could Redefine First-in-Human Trials in Latin America

ANVISA Cuts Device Review to 6 Months; COFEPRIS Aligns With ICH E6(R3) | Global Trial Accelerators

ANVISA Cuts Medical Device Review Timeline by 6 Months

⚡ Argentina cuts trial approvals to 62 days

Navigated to Panama Vs. Colombia Vs. Chile: Which LATAM Cou… | bioaccess® We accept max 8 new FIH programs per quarter to protect our 12-month guarantee. Panama Vs. Colombia Vs. Chile: Which LATAM Country For Your FIH Trial? By Julio G. Martinez-Clark, CEO, bioaccess® Choosing the right location for a At bioaccess®, we specialize in navigating the complexities of clinical trials in Latin Americ

Panama vs Colombia vs Chile: Which LATAM Country for Your FIH Trial?

🇵🇪 Innovation is moving into Latin America

pharmaceutical regulatory approvals in Brazil frequently experience delays that extend market entry timelines and increase regulatory risk. While many organizations attribute delays to missing documentation or procedural compliance issues, regulatory assessments increasingly show that approval challenges often originate much earlier in the development lifecycle According to observations from the

Brazil’s Approval Delays Are Forcing Smarter Trial Strategies

🌍 Why Latin America Is Back on Sponsors’ Radar

Mexico Advances Faster Pathways for Medical Device Market Entry

⚡ What’s Behind Faster Drug Development Paths?

Partner With Bioaccess CRO: A Step-By-Step Approach For Success By Julio G. Martinez-Clark, CEO, bioaccess® In the fast-paced world of clinical research, healthcare startups face a critical challenge: navigating the complexities of With a multitude of CROs available, how can startups ensure they select the right partner to maximize their chances of success during this pivotal phase? This article

A Step-by-Step Path to Running Early-Phase Trials in Latin America

📊 Mexico Invests $400M — What This Means for MedTech

Latin America Steps Into Global Regulatory Convergence